Skip to: Curated Story Group 1
lifesciencesreview

Advertise

with us

    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Topics
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Business Services
    Business Services
    Business Services
    Business Services
    Business Services
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Pharmacy Management
    Regulatory Services
  • CXO Insights
  • Vendor Viewpoint
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • CXO Awards
8CHALLENGES AND OPPORTUNITIES FORBy Bobby Prill, Director, Data Science and AI, Computational Biology and Data Sciences, Ferring Research Institute, Inc. and Yong Yue, Senior Director, Computational Biology and Data Sciences, Ferring Research Institute, Inc.IN MY OPINIONf conventional drug discovery is akin feeling around in the dark, artificial intelligence (AI) is portrayed as a high-tech flashlight, an essential tool to light the way. Unbridled enthusiasm for AI drug discovery is driving massive investment in AI-drug startups and enticing established pharmaceutical companies to recruit AI talent and seek partnerships with AI-drug outfits. In this moment of rapid technological change, it is a IAI IN DRUG DISCOVERY Bobby Prill
< Page 7 | Page 9 >